Furthermore, combined treatment with OX40 and GITR ligand fusion proteins enhanced both CD4+ and CD8+ T cell activation and antitumor activity in CT26 colon cancer–bearing mice (84). This evidence concerns the gene TNFRSF4 and malignant colon neoplasm.